| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
Divisions of Hematology/Oncology [J. S. P.] and Developmental Biology [J. M. P., L. S. K., K. T., J. L. D.], Childrens Hospital Research Foundation and University of Cincinnati College of Medicine, Cincinnati, Ohio 45229-3039, and MRC Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom [D. G. J.]
Previous studies of tumor cell-associated procoagulants and fibrinolytic factors have strongly suggested that local thrombin and plasmin generation may be important in tumor growth and dissemination. Given that one central target of both of these serine proteases is fibrin(ogen), a logical extension of this hypothesis is that local fibrin deposition and dissolution may be key determinants of tumor progression. In this paper, the role of fibrin(ogen) and its degradation products in the growth and spontaneous metastasis of Lewis lung carcinoma was directly examined by comparative studies of control and fibrinogen-deficient mice. Fibrinogen deficiency was found to have no effect on the time required for the formation of palpable tumors, tumor angiogenesis, overall tumor architecture, or primary (s.c.) or secondary (pulmonary) tumor growth. However, fibrinogen deficiency markedly reduced the incidence of spontaneous macroscopic metastases in the lung and regional lymph nodes, a process that occurred relatively late in tumor development. Furthermore, a significant quantitative reduction in pulmonary micrometastases was observed in fibrinogen-deficient mice. Quantitative analyses of pulmonary micrometastases in primary tumor-bearing mice indicated that spontaneous showering of tumor cell emboli into the lung was robust, regardless of animal genotype. Hence, our results suggest fibrin(ogen) plays an important role in spontaneous metastasis, facilitating the stable adhesion and/or survival of metastatic emboli after tumor cell intravasation. These studies suggest that therapeutic strategies focusing on hemostatic factors may be effective in controlling solid tumor metastasis, particularly if used for the treatment of micrometastatic disease.
This article has been cited by other articles:
![]() |
M. Zangari, L. M. Fink, F. Elice, F. Zhan, D. M. Adcock, and G. J. Tricot Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents J. Clin. Oncol., October 10, 2009; 27(29): 4865 - 4873. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Boccaccio and P. M. Comoglio Genetic Link Between Cancer and Thrombosis J. Clin. Oncol., October 10, 2009; 27(29): 4827 - 4833. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sousou and A. A. Khorana New Insights Into Cancer-Associated Thrombosis Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 316 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Alves, S. Yakovlev, L. Medved, and K. Konstantopoulos Biomolecular Characterization of CD44-Fibrin(ogen) Binding: DISTINCT MOLECULAR REQUIREMENTS MEDIATE BINDING OF STANDARD AND VARIANT ISOFORMS OF CD44 TO IMMOBILIZED FIBRIN(OGEN) J. Biol. Chem., January 9, 2009; 284(2): 1177 - 1189. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Alves, M. M. Burdick, S. N. Thomas, P. Pawar, and K. Konstantopoulos The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion Am J Physiol Cell Physiol, April 1, 2008; 294(4): C907 - C916. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Palumbo, K. E. Talmage, J. V. Massari, C. M. La Jeunesse, M. J. Flick, K. W. Kombrinck, Z. Hu, K. A. Barney, and J. L. Degen Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms Blood, July 1, 2007; 110(1): 133 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yang, H. Avila, H. Wang, J. Trevino, G. E. Gallick, Y. Kitadai, T. Sasaki, and D. D. Boyd Plasticity in Urokinase-Type Plasminogen Activator Receptor (uPAR) Display in Colon Cancer Yields Metastable Subpopulations Oscillating in Cell Surface uPAR Density--Implications in Tumor Progression Cancer Res., August 15, 2006; 66(16): 7957 - 7967. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bloomston, J. X. Zhou, A. S. Rosemurgy, W. Frankel, C. A. Muro-Cacho, and T. J. Yeatman Fibrinogen {gamma} Overexpression in Pancreatic Cancer Identified by Large-scale Proteomic Analysis of Serum Samples. Cancer Res., March 1, 2006; 66(5): 2592 - 2599. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yamashita, J. Kitayama, and H. Nagawa Hyperfibrinogenemia is a Useful Predictor for Lymphatic Metastasis in Human Gastric Cancer Jpn. J. Clin. Oncol., October 1, 2005; 35(10): 595 - 600. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Belting, J. Ahamed, and W. Ruf Signaling of the Tissue Factor Coagulation Pathway in Angiogenesis and Cancer Arterioscler Thromb Vasc Biol, August 1, 2005; 25(8): 1545 - 1550. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Criscuoli, M. Nguyen, and B. P. Eliceiri Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability Blood, February 15, 2005; 105(4): 1508 - 1514. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Weiler A platelet cloak for tumor cells Blood, January 1, 2005; 105(1): 5 - 6. [Full Text] [PDF] |
||||
![]() |
J. S. Palumbo, K. E. Talmage, J. V. Massari, C. M. La Jeunesse, M. J. Flick, K. W. Kombrinck, M. Jirouskova, and J. L. Degen Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells Blood, January 1, 2005; 105(1): 178 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Im, W. Fu, H. Wang, S. K. Bhatia, D. A. Hammer, M. A. Kowalska, and R. J. Muschel Coagulation Facilitates Tumor Cell Spreading in the Pulmonary Vasculature during Early Metastatic Colony Formation Cancer Res., December 1, 2004; 64(23): 8613 - 8619. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Shi, B. Gangadharan, L. F. Brass, W. Ruf, and B. M. Mueller Protease-Activated Receptors (PAR1 and PAR2) Contribute to Tumor Cell Motility and Metastasis Mol. Cancer Res., July 1, 2004; 2(7): 395 - 402. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Staton, N. J. Brown, G. R. Rodgers, K. P. Corke, S. Tazzyman, J. C. E. Underwood, and C. E. Lewis Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo Blood, January 15, 2004; 103(2): 601 - 606. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Palumbo, K. E. Talmage, H. Liu, C. M. La Jeunesse, D. P. Witte, and J. L. Degen Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency Blood, October 15, 2003; 102(8): 2819 - 2827. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |